GSK plc (LON:GSK) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of GSK plc (LON:GSK) have received an average rating of “Moderate Buy” from the seven brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is GBX 1,842.50 ($23.20).

A number of brokerages recently commented on GSK. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a report on Monday, July 29th. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 1,820 ($22.92) price objective on shares of GSK in a research note on Tuesday, September 10th. Shore Capital reissued a “buy” rating on shares of GSK in a research report on Wednesday, August 28th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 1,850 ($23.30) price target on shares of GSK in a report on Tuesday, September 3rd.

GSK Stock Performance

LON GSK opened at GBX 1,325 ($16.69) on Monday. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 123.04. GSK has a twelve month low of GBX 1,282.50 ($16.15) and a twelve month high of GBX 1,823.50 ($22.96). The business has a 50-day moving average price of GBX 1,460.77 and a 200-day moving average price of GBX 1,564.08. The firm has a market cap of £54.06 billion, a price-to-earnings ratio of 1,172.57, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.

GSK Announces Dividend

The company also recently disclosed a dividend, which will be paid on Thursday, January 9th. Investors of record on Thursday, November 14th will be paid a GBX 15 ($0.19) dividend. The ex-dividend date of this dividend is Thursday, November 14th. This represents a yield of 1.03%. GSK’s dividend payout ratio (DPR) is currently 5,309.73%.

Insider Activity at GSK

In related news, insider Jonathan Symonds purchased 7,150 shares of GSK stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average cost of GBX 1,394 ($17.55) per share, with a total value of £99,671 ($125,514.42). Also, insider Elizabeth (Liz) McKee Anderson acquired 446 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The shares were bought at an average cost of GBX 2,051 ($25.83) per share, for a total transaction of £9,147.46 ($11,519.28). Insiders bought 7,604 shares of company stock worth $10,893,038 over the last three months. 1.61% of the stock is owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.